Epacadostat

DGAP-News: Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway

Thursday, March 26, 2020 - 8:01am

DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication

Key Points: 
  • DGAP-News: Secarna Pharmaceuticals GmbH & Co. KG / Key word(s): Scientific publication
    Newly published data in Cancer Immunology, Immunotherapy support the potential of Secarna Pharmaceuticals' LNA-modified ASOs to effectively block important immunosuppressive pathway
    The issuer is solely responsible for the content of this announcement.
  • Both targets are catalytic enzymes that play a key role in an important immunosuppressive pathway - the degradation of tryptophan into kynurenine.
  • Secarna's approach also was shown to be synergistic with one of the clinically most advanced IDO1-specific small molecule inhibitors (epacadostat).
  • The published data show that treatment of cancer cells with LNAplusTM-modified ASOs specific for IDO1 and TDO2 lead to potent target knockdown in vitro.

BriaCell Doses First Patient in Phase I/IIa Study Evaluating Bria-IMT™ in Combination with INCMGA00012 and Epacadostat in Patients with Advanced Breast Cancer

Monday, October 7, 2019 - 11:30am

Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCells lead candidate, Bria-IMT in combination with Incytes INCMGA00012 and epacadostat in patients with advanced breast cancer.

Key Points: 
  • Patient dosing has begun in the Phase I/IIa study evaluating the anti-tumor effects of BriaCells lead candidate, Bria-IMT in combination with Incytes INCMGA00012 and epacadostat in patients with advanced breast cancer.
  • A subsequent group of patients will be treated with the triple combination of the Bria-IMT with INCMGA00012 and epacadostat.
  • The starting dose of epacadostat has been established to be safe when given in combination with INCMGA00012 in patients with cancer.
  • Phase I/IIa clinical trial is an open-label, multi-center study to evaluate the safety and efficacy of Bria-IMT in combination with INCMGA00012, and epacadostat in patients with advanced breast cancer.

UCSF Doses First Patient in Triple Combination Clinical Trial of OncoSec's TAVO™, Epacadostat and KEYTRUDA® for the Treatment of Unresectable Squamous Cell Head and Neck Cancer

Thursday, May 23, 2019 - 1:30pm

The triple combination of IL-12, IDO1 and anti-PD-1 monoclonal antibody is a first-of-its-kind clinical trial and is seeking to exploit individual anti-tumor properties of each modality.

Key Points: 
  • The triple combination of IL-12, IDO1 and anti-PD-1 monoclonal antibody is a first-of-its-kind clinical trial and is seeking to exploit individual anti-tumor properties of each modality.
  • The goal of the study is to evaluate this three-way combination in SCCHN cancer and, if promising, to potentially evaluate the triple combination in other tumor types.
  • TRIFECTA is an investigator-initiated, single-arm, open-label clinical trial in which 35 evaluable SCCHN patients will receive TAVO, pembrolizumab, and epacadostat.
  • OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target and attack cancer.